[Comparative effectiveness hepatotropic activity remaxol and Essentiale N in chronic viral hepatitis].
Studied hepatotropic activity remaxol and Essentiale N with chronic viral hepatitis (hug) and: 45 patients received the drug remaxol (intravenous drip, 400 ml per day, 10 days), 45 patients Essentiale N (intravenous bolus, 5 ml per day, 10 days). The efficacy was assessed by clinical symptoms, activity ofAlt, AST, bilirubin, alkaline phosphatase, molecules of average weight (MSM), and total effective concentration of albumin (ECA). Remaxol when hug had a hepatotropic effect comparable with Essentiale N, but more effectively cut short asteno vegetative, dyspeptic, cholestatic and intoxication syndrome, which was confirmed by the significantly low values of MSM and high rates of ECA. The inclusion remaxol in the treatment of patients hug should be considered pathogenetically justified, clinically justified and promising.
V F
VF
Pavelkina
N P
NP
Ampleeva
D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008111:Liver Function Tests; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use*; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000975:Antioxidants; D010713:Phosphatidylcholines; C555877:Remaxol; D013386:Succinates; C011246:essential 303 forte